ALLO
NASDAQ · Biotechnology
Allogene Therapeutics Inc
$2.01
+0.04 (+2.03%)
Open$1.98
Previous Close$1.97
Day High$2.03
Day Low$1.96
52W High$4.46
52W Low$0.98
Volume—
Avg Volume7.06M
Market Cap695.49M
P/E Ratio—
EPS$-0.87
SectorBiotechnology
Analyst Ratings
Strong Buy
18 analysts
Price Target
+995.0% upside
Current
$2.01
$2.01
Target
$22.01
$22.01
$17.29
$22.01 avg
$30.07
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 52.71M | 52.93M | 41.75M |
| Net Income | 7.77M | 8.17M | 5.40M |
| Profit Margin | 14.7% | 15.4% | 12.9% |
| EBITDA | 12.72M | 14.19M | 11.69M |
| Free Cash Flow | 7.78M | 12.29M | 5.60M |
| Rev Growth | +19.4% | -7.3% | -1.4% |
| Debt/Equity | 1.42 | 1.47 | 1.26 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $246.04 | +0.89% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $410.95 | +1.51% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $133.21 | +1.80% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $496.07 | +2.49% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $784.36 | +1.59% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $219.20 | +1.43% | 35.2 | 28.41B |